MANZ AG/ DE000A0JQ5U3 /
6/2/2023 9:38:11 PM | Chg. -0.250 | Volume | Bid9:38:12 PM | Ask9:38:12 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
20.650EUR | -1.20% | 1,205 Turnover: 24,950.700 |
20.650Bid Size: 160 | 21.000Ask Size: 160 | 159.65 mill.EUR | 0.00% | - |
GlobeNewswire
9/16/2021
Boehringer Ingelheim and OSE Immunotherapeutics Present Phase 1 Results with First-in-Class SIRPα I...
GlobeNewswire
9/13/2021
Boehringer Ingelheim and OSE Immunotherapeutics to Present Phase 1 Results with First-in-Class SIRPα...
GlobeNewswire
5/17/2021
“Everything is Neo,” The Revolutionary Launch of Duravit’s D-Neo Series Designed by Bertrand Lejoly
GlobeNewswire
10/20/2020
Volkswagen Adopts NXP Battery Management Solutions for its MEB Electrical Vehicle Platform
GlobeNewswire
7/28/2020
Comstock Mining Announces Second Quarter 2020 Results; Initiated Delivery of Comstock Mercury Remedi...
GlobeNewswire
7/21/2020
Comstock Mining Announces Positive Net Income for Second Quarter; Readies Transport of Mercury Remed...
GlobeNewswire
7/7/2020
Comstock Mining Announces Second Quarter 2020 Update; Goal Drives Strategic Value Targets
GlobeNewswire
5/2/2019
Wolters Kluwer Has Sold 40% Stake in Austrian Information Services Specialist
GlobeNewswire
7/20/2018
Children’s Club Debuts CURATE; An Elevated Showcase for Global Children’s Wear Collections
GlobeNewswire
12/11/2017
argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cut...
GlobeNewswire
12/11/2017
argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cut...
GlobeNewswire
8/8/2017
Thin Film Photovoltaics Market, 2030 - The Need for Next Generation PV Technologies
GlobeNewswire
6/14/2017
argenx presents update on Phase I data from ARGX-110 expansion study in patients with cutaneous T-ce...
GlobeNewswire
6/14/2017
argenx presents update on Phase I data from ARGX-110 expansion study in patients with cutaneous T-ce...
GlobeNewswire
4/12/2017
argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients